The European Medicines Agency (EMA) on 29 March 2022 initiated a rolling review process of PHH-1V, a vaccine against SARS-CoV-2 developed by the Spanish pharmaceutical company HIPRA.
The vaccine is intended to be administered intramuscularly as a booster dose in adults who have already completed a first vaccination schedule with another SARS-CoV-2 vaccine using a different technology.
PHH-1V is a recombinant protein vaccine. It contains two synthetic versions of fragments of the SARS-CoV-2...